Literature DB >> 2441861

Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.

C R Fairchild, S P Ivy, C S Kao-Shan, J Whang-Peng, N Rosen, M A Israel, P W Melera, K H Cowan, M E Goldsmith.   

Abstract

An MCF-7 human breast cancer cell line was selected which was 200-fold more resistant to Adriamycin than the wild type cell line. This Adriamycin-resistant (AdrR) cell line exhibited a multidrug-resistant phenotype and was cross-resistant to a wide range of antineoplastic agents including Vinca alkaloids, anthracyclines, and epipodophyllotoxins. Cytogenetic analysis of the AdrR cell line showed the presence of homogeneously staining regions on several chromosomes which were not present in the parental cell line. Using the technique of in-gel renaturation, DNA sequences which were amplified 50- to 100-fold in the AdrR cell line and which covered a total of over 140 kilobases were isolated. In addition, AdrR cells were found to contain amplified and overexpressed sequences which were homologous to hamster P-glycoprotein gene sequences. A hamster cDNA P-glycoprotein gene probe was used to screen a lambda gt10 cDNA library made from human AdrR cell line mRNA and human cDNA sequences homologous to the P-glycoprotein gene were isolated. Hybridization studies with the cloned human cDNA (pADR1) showed that the AdrR MCF-7 cell line contained a 60-fold amplification of this DNA sequence and that polyadenylated mRNA from the AdrR cell line contained a 4.8-kilobase transcript which was overexpressed 45-fold. There was a direct correlation between DNA and RNA copy number of this sequence and level of resistance among several MCF-7 Adriamycin-resistant cell lines. In situ hybridization studies demonstrated that the human P-glycoprotein gene sequence was found on chromosome 7q21.1 in normal human lymphocytes and that amplified DNA sequences isolated from the AdrR MCF-7 cells by the in-gel hybridization technique were linked to the human P-glycoprotein sequences in the homogeneously staining regions in the AdrR cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441861

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

2.  DNA amplification is rare in normal human cells.

Authors:  J A Wright; H S Smith; F M Watt; M C Hancock; D L Hudson; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Authors:  Gauri Patwardhan; Vineet Gupta; Juowen Huang; Xin Gu; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2010-03-16       Impact factor: 5.858

4.  Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer.

Authors:  S Schiemann; M Schwirzke; N Brünner; U H Weidle
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

5.  Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization.

Authors:  Joseph M Langenhan; Noël R Peters; Ilia A Guzei; F Michael Hoffmann; Jon S Thorson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-16       Impact factor: 11.205

6.  Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.

Authors:  L Wang; C P Yang; S B Horwitz; P A Trail; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Authors:  J Bray; J Sludden; M J Griffin; M Cole; M Verrill; D Jamieson; A V Boddy
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

9.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

10.  A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Authors:  Gauri A Patwardhan; Qian-Jin Zhang; Dongmei Yin; Vineet Gupta; Jianxiong Bao; Can E Senkal; Besim Ogretmen; Myles C Cabot; Girish V Shah; Paul W Sylvester; S Michal Jazwinski; Yong-Yu Liu
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.